Early intervention in post-transplant lymphoproliferative disorders based on Epstein–Barr viral load
- 1 July 2000
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 26 (2) , 199-201
- https://doi.org/10.1038/sj.bmt.1702492
Abstract
Using a real-time quantitative PCR assay, we identified two patients with EBV-related lymphoproliferative disorders at a very early stage. Both had received an unmanipulated bone marrow transplant with anti-thymocyte globulin for conditioning. To estimate virus-specific immunity, the frequencies of EBV-specific CD8+ T cells were measured using an enzyme-linked immunospot assay. The frequencies of EBV-specific CD8+ T cells of the two were 3.2 and 7.7%, respectively, which had possibly expanded in vivo. After withdrawing the immunosuppressive agents or administering donor lymphocytes transfusion, their symptoms regressed in parallel with the viral load. Bone Marrow Transplantation (2000) 26, 199–201.Keywords
This publication has 8 references indexed in Scilit:
- Increased frequency of antigen-specific CD8+ cytotoxic T lymphocytes infiltrating an Epstein-Barr virus–associated gastric carcinomaJournal of Clinical Investigation, 1999
- B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcomeBone Marrow Transplantation, 1999
- Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppressionThe Lancet, 1998
- Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant RecipientsBlood, 1998
- Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant RecipientsBlood, 1998
- Semiquantitative Epstein-Barr Virus (EBV) Polymerase Chain Reaction for the Determination of Patients at Risk for EBV-Induced Lymphoproliferative Disease After Stem Cell TransplantationBlood, 1998
- Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Epstein-Barr infection after bone marrow transplantation [letter]Blood, 1994